Literature DB >> 23456355

Risk factors for recurrence following complete cytoreductive surgery and HIPEC in colorectal cancer-derived peritoneal surface malignancies.

Ingmar Königsrainer1, Philipp Horvath, Florian Struller, Viola Forkl, Alfred Königsrainer, Stefan Beckert.   

Abstract

PURPOSE: Recurrent disease following complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a relevant clinical scenario. We aimed to determine risk factors for recurrence.
METHODS: Prospectively collected data of patients enrolled in the Peritoneal Surface Malignancy Program at the University of Tübingen between 2005 and 2011 were retrospectively analyzed. All patients were treated by standardized CRS and HIPEC. Recurrence was defined either radiographically by CT, PET-CT scan, or reoperation.
RESULTS: Fifty-two patients received complete CRS (CC-0/CC-1) and HIPEC. Median time to recurrence was 229 days (103-1,028). Overall recurrence rate within follow-up was 48 %. Of patients with recurrent disease, 44 % experienced extraperitoneal systemic tumor spread. In multivariate analysis, grading of ≥ 3 was shown as an independent risk factor for recurrent disease, while a trend was observed for maximal tumor load in the upper abdominal region. Clinical parameters did not show an impact on recurrence.
CONCLUSIONS: Primary tumor grading seems to be an independent risk factor for recurrence following complete CRS and HIPEC in colorectal cancer-derived peritoneal surface malignancies.

Entities:  

Mesh:

Year:  2013        PMID: 23456355     DOI: 10.1007/s00423-013-1065-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  18 in total

1.  Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma.

Authors:  J C Cusack; G G Giacco; K Cleary; B S Davidson; F Izzo; J Skibber; J Yen; S A Curley
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

2.  Prediction of distant metastases after curative surgery for rectal cancer.

Authors:  Klaus Günther; Otto Dworak; Stefan Remke; Rafael Pflüger; Susanne Merkel; Werner Hohenberger; Marc A Reymond
Journal:  J Surg Res       Date:  2002-03       Impact factor: 2.192

3.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

4.  Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.

Authors:  Vic J Verwaal; Henk Boot; Berthe M P Aleman; Harm van Tinteren; Frans A N Zoetmulder
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

5.  Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.

Authors:  Terence C Chua; Tristan D Yan; Michelle E Smigielski; Katherine J Zhu; Keh M Ng; Jing Zhao; David L Morris
Journal:  Ann Surg Oncol       Date:  2009-04-23       Impact factor: 5.344

6.  8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Sjoerd Bruin; Henk Boot; Gooike van Slooten; Harm van Tinteren
Journal:  Ann Surg Oncol       Date:  2008-06-03       Impact factor: 5.344

7.  Peritonectomy procedures.

Authors:  P H Sugarbaker
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

8.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?

Authors:  Tristan D Yan; David L Morris
Journal:  Ann Surg       Date:  2008-11       Impact factor: 12.969

9.  Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.

Authors:  Dominique Elias; Diane Goéré; Daniela Di Pietrantonio; Valérie Boige; David Malka; Niaz Kohneh-Shahri; Clarisse Dromain; Michel Ducreux
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

10.  Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

Authors:  Lana Bijelic; Tristan D Yan; Paul H Sugarbaker
Journal:  Ann Surg Oncol       Date:  2007-05-15       Impact factor: 5.344

View more
  9 in total

1.  Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: Indications for hyperthermic intraperitoneal chemoperfusion therapy.

Authors:  Yinuo Tu; Yunhong Tian; Yinbing Wu; Shuzhong Cui
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

2.  Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei.

Authors:  Philipp Horvath; Stefan Beckert; Florian Struller; Alfred Königsrainer; Ingmar Königsrainer
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

3.  iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Authors:  Lorena Simón-Gracia; Hedi Hunt; Pablo Scodeller; Jens Gaitzsch; Venkata Ramana Kotamraju; Kazuki N Sugahara; Olav Tammik; Erkki Ruoslahti; Giuseppe Battaglia; Tambet Teesalu
Journal:  Biomaterials       Date:  2016-07-20       Impact factor: 12.479

4.  Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review.

Authors:  Emma C Hulshof; Lifani Lim; Ignace H J T de Hingh; Hans Gelderblom; Henk-Jan Guchelaar; Maarten J Deenen
Journal:  Front Pharmacol       Date:  2020-10-06       Impact factor: 5.810

5.  Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Authors:  Emily Wonder; Lorena Simón-Gracia; Pablo Scodeller; Ramsey N Majzoub; Venkata Ramana Kotamraju; Kai K Ewert; Tambet Teesalu; Cyrus R Safinya
Journal:  Biomaterials       Date:  2018-03-02       Impact factor: 12.479

Review 6.  Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes.

Authors:  Harveshp Mogal; Konstantinos Chouliaras; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  J Gastrointest Oncol       Date:  2016-02

7.  Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.

Authors:  Kyoji Ito; Nobuyuki Takemura; Fuyuki Inagaki; Fuminori Mihara; Toshiaki Kurokawa; Yoshimasa Gohda; Tomomichi Kiyomatsu; Hideaki Yano; Norihiro Kokudo
Journal:  World J Surg Oncol       Date:  2019-06-13       Impact factor: 2.754

8.  Analysis of Bacterial and Fungal Infections after Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Observational Single-Centre Study.

Authors:  Talat A M Albukhari; Hanaa Nafady-Hego; Hamed Elgendy; Hanan M Abd Elmoneim; Asmaa Nafady; Abdulaziz M Alzahrani
Journal:  Int J Microbiol       Date:  2019-08-01

9.  Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy.

Authors:  Mohsen Rezaeian; Amir Sedaghatkish; M Soltani
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.